European journal of rheumatology最新文献

{"title":"B-Scan Ultrasound Evaluation for Uveitis in Inflammatory Arthropathies: Systematic Review.","authors":"José Alexandre Mendonça,&nbsp;Rafael de Figueiredo Torres Caivano,&nbsp;Isabella Casani Rech,&nbsp;Isabella Siste de Almeida Aoki,&nbsp;Caique Chagas Cavuto","doi":"10.5152/eurjrheum.2023.22054","DOIUrl":"10.5152/eurjrheum.2023.22054","url":null,"abstract":"<p><p>The ocular inflammatory process may be associated with autoimmune inflammatory joint damage and can be better recovered by B-mode ultrasound, being little explored in the absent eye evaluation. This study aimed to conduct a systematic review using the Patients or Problem, Intervention, Control or Comparison, Outcomes strategy: uveitis; ultrasound, arthritis, and diagnosis. Clinical trials, meta-analysis, and randomized controlled trials that specifically address the scope of this study will be evaluated. For the search in the database, a choice of controlled vocabulary will be used with the MEDLINE MeSH platform (Medical Subject Headings). The articles must be dated from the year 2010 until the year 2020. To charting methods will be used Preferred Reporting Items for Systematic Reviews and Meta-Analyses Flow Diagram and risk of bias: the Cochrane risk of bias tool. Grade of recommendation assessment: Grading of Recommendations Assessment, Development, and Evaluation Group guidelines. Of 2909 studies, only 13 studies were included, which evaluated the use of B-mode ultrasound to assess anterior and intermediate uveitis and complications, and 5 cases showed an association of vitreitis. B-mode ultrasound can be an important benefit of complementing clinical evaluation in patients with the uveal inflammatory process associated with several autoimmune arthropathies, but more studies with better-elaborated methodology design will be necessary.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"71-83"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/57/ejr-10-2-71.PMC10544347.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9824659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients.","authors":"Sinakhanım Huseynzada,&nbsp;Tuba Yüce İnel,&nbsp;Farid Hajiyev,&nbsp;Aydan Köken Avşar,&nbsp;Ali Balcı,&nbsp;Hale Akpınar,&nbsp;Fatoş Önen,&nbsp;İsmail Sarı","doi":"10.5152/eurjrheum.2023.22049","DOIUrl":"10.5152/eurjrheum.2023.22049","url":null,"abstract":"<p><strong>Objective: </strong>Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect, systemic immunosuppression is not expected, and this may have a negative effect on the extra-intestinal symptoms of inflammatory bowel disease, particularly spondyloarthritis. Currently, there is limited data regarding the effect of vedolizumab on spondyloarthritis symptoms. We aimed to investigate whether vedolizumab has an effect on the occurrence of rheumatological symptoms and the clinical course of patients who have spondyloarthritis.</p><p><strong>Methods: </strong>Thirty-nine adult inflammatory bowel disease patients who were followed up in the Gastroenterology Clinic and treated with vedolizumab were included in the study. Patients were reviewed in terms of rheumatological manifestations. The occurrence of new musculoskeletal findings during the vedolizumab treatment was recorded. Patients with a former diagnosis of spondyloarthritis were evaluated for the activity of axial and peripheral manifestations during the vedolizumab.</p><p><strong>Results: </strong>There were 39 inflammatory bowel disease patients (29 Crohn's disease, 10 ulcerative colitis, 48.7% (n = 19) male) who had been treated with vedolizumab. The mean age of the patients was 41.4 ± 15.7 years, and the duration of inflammatory bowel disease was 10.4 ± 7.5 years. A total of 17 (44%) patients had accompanying spondyloarthritis findings (mean age 47.08 ± 15.325 years and 58.8% M). Seven patients had axial dominant symptoms and 6 of them were in an active disease state before vedolizumab. During vedolizumab, all but 1 continued to be active. There were 14 patients with arthritis/arthralgias before vedolizumab and only 3 had improvement with therapy. On the other hand, there were 3 patients who had new-onset arthralgias/arthritis with vedolizumab. In total, 6 patients needed to stop vedolizumab because of spondyloarthritis activation (n = 2) and uncontrolled inflammatory bowel disease (n = 4), respectively.</p><p><strong>Conclusion: </strong>Treatment with vedolizumab seems no effect on both the occurrence and the course of rheumatological manifestations in inflammatory bowel disease patients. Further studies are required to replicate our results.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"50-56"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/7c/ejr-10-2-50.PMC10542484.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9831562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound Examination for a Traumatic Thumb Injury: Simple and Straightforward.","authors":"Berkay Yalçınkaya,&nbsp;Hasan Ocak,&nbsp;Pelin Analay,&nbsp;Levent Özçakar","doi":"10.5152/eurjrheum.2023.23006","DOIUrl":"10.5152/eurjrheum.2023.23006","url":null,"abstract":"Corresponding author: Berkay Yalçınkaya E-mail: berkay0lka@gmail.com Received: January 21, 2023 Accepted: May 09, 2023 Publication Date: July 13, 2023 A 29-year-old man (psychiatry resident) was seen for acute right-hand pain on the thenar side. He described the pain to have ensued after a fall episode 3 days ago (during walking). He declared that the pain was worse upon palpation and during hand movements. He denied any neurological symptoms and the rest of his medical history was noncontributory.","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"90-91"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/c2/ejr-10-2-90.PMC10544409.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9828300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoglobulin G4-Associated Rosai-Dorfman Disease: Report of 3 Cases.","authors":"Jesica Romina Gallo,&nbsp;Sergio Paira,&nbsp;Gabriela Hernández-Molina,&nbsp;Jesús Delgado-de la Mora,&nbsp;Daniel Montante-Montes de Oca,&nbsp;Eduardo Martín-Nares","doi":"10.5152/eurjrheum.2023.22064","DOIUrl":"10.5152/eurjrheum.2023.22064","url":null,"abstract":"<p><p>Rosai-Dorfman disease is characterized by dilated lymph node sinuses filled with lymphocytes, plasma cells, and histiocytes. Many of these histiocytes classically exhibit emperipolesis of lymphocytes and plasma cells. Abundant immunoglobulin G4+ plasma cells occur in some cases, and a potential relationship with immunoglobulin G4-related disease has been suggested. Here, we report 3 cases of immunoglobulin G4-associated Rosai-Dorfman disease. Immunoglobulin G4-related disease was suspected based on immunoglobulin G4+ plasma cell infiltration, but the final diagnosis was immunoglobulin G4-associated Rosai-Dorfman disease. At present, the evidence does not support a link between immunoglobulin G4-associated Rosai-Dorfman disease and immunoglobulin G4-related disease, and one condition should not be considered part of the spectrum of the other. We believe it is of paramount importance to increase the awareness of immunoglobulin G4-associated Rosai-Dorfman disease for pathologists who interpret the biopsies and clinicians who integrate the diagnosis and treat such patients to not overdiagnose immunoglobulin G4-related disease.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"57-61"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/42/ejr-10-2-57.PMC10543072.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9832052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Behcet's Syndrome Resembling Takayasu's Arteritis with the Distribution of Arterial Involvement: A Case Report and Literature Review.","authors":"Gamze Akkuzu,&nbsp;Duygu Sevinç Özgür,&nbsp;Bilgin Karaalioğlu,&nbsp;Melek Yalçın Mutlu,&nbsp;Fatih Yıldırım,&nbsp;Mustafa Erdoğan,&nbsp;Burak İnce,&nbsp;Cemal Bes","doi":"10.5152/eurjrheum.2023.22043","DOIUrl":"10.5152/eurjrheum.2023.22043","url":null,"abstract":"<p><p>Behcet's syndrome is a variable vessel vasculitis characterized by recurrent oral and genital ulcers with concomitant skin, ocular, neurologic, gastrointestinal, and joint involvement. Herein, we present a patient who was diagnosed with Behcet's syndrome, which with magnetic resonance angiography showed occlusion of the right subclavian artery at the level of the thoracic outlet and reverse flow in the right vertebral artery consistent with subclavian steal syndrome. In addition, partial narrowing was noted in the left renal artery. The distribution of arterial involvement resembled Takayasu's arteritis, although the presence of mucocutaneous lesions, male gender, history of deep vein thrombosis, and HLA-B51 positivity favored a diagnosis of vasculo-Behçet's syndrome. We treated the patient with methylprednisolone and cyclophosphamide. After the regression of vascular inflammation with immunosuppressive therapy, stenting was performed in the left renal artery.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"62-66"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/21/41/ejr-10-2-62.PMC10544313.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9978490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypereosinophilic Syndrome with Endomyocarditis: Identification by Next-Generation Sequencing of the JAK2-V617F Mutation.","authors":"Ruta Tesfamicael,&nbsp;Thanda Aung,&nbsp;Thomas Domin Lee,&nbsp;Ernest Brahn","doi":"10.5152/eurjrheum.2023.22123","DOIUrl":"10.5152/eurjrheum.2023.22123","url":null,"abstract":"<p><p>Hypereosinophilic syndrome requires a peripheral absolute eosinophil count of ≥1.5 × 109 /L with clinical manifestations attributable to peripheral or tissue hypereosinophilia. Clinical manifestations can vary greatly, with the majority of patients relatively asymptomatic and the eosinophilia detected incidentally. However, in a minority of hypereosinophilia cases, they may present with severe lifethreatening organ dysfunction affecting skin, lung, heart, gastrointestinal tract, and nervous system. A case of hypereosinophilia with potentially life-threatening cardiovascular involvement is discussed. Initial laboratory investigations showed an elevated white blood cell count with 60% eosinophils. An endomyocardial biopsy revealed eosinophilic endomyocarditis with granuloma, rare giant cells, and no vasculitis, microorganisms, or malignancy. Her presentation met the criteria for either hypereosinophilic syndrome or eosinophilic granulomatosis with polyangitis. Molecular genetic analysis was negative for myelodysplastic syndrome panel/ Platelet Derived Growth Factor Receptor Beta (PDGFRB) (5q32)/Fibroblast Growth Factor Receptor 1 (FGFR1) Fluorescence In Situ Hybridization (FISH), Feline McDonough Sarcoma-related Tyrosine Kinase 3 (FLT3) Internal Tandem Duplication (ITD) mutation, Calregulin (CALR) exon 9 mutation, and T-cell gene rearrangement/polymerase chain reaction. Bone marrow biopsy revealed a mildly hypocellular marrow with multilineage hematopoiesis,+ megakaryocyte dysplasia, and focal eosinophilia. No excess blasts, no monotypic B-cell population, and no discrete pan T-cell aberrancies were found. Bone marrow cytogenetic studies showed a normal signal pattern for myeloproliferative neoplasms panel/Sec1 Family Domain Containing 2 (SCFD2)-Ligand of Numb Protein-X (LNX)-Platelet-derived Growth Factor Receptor Alpha (PDGFRA) fluorescence in situ hybridization with a normal karyotype of 46 XX. Next-generation sequencing, however, was positive for the JAK2-V617F mutation, a rare molecular abnormality in hypereosinophilic syndrome. The prevalence ranges from approximately 0% to 4%. The JAK2 point mutation leads to aberrant tyrosine phosphorylation and increased cytokine activation. The case demonstrates the complexity and challenging nature of advanced diagnostic opportunities in hypereosinophilia and the potential use, in select subsets, of targeted treatments such as tyrosine kinase inhibitors.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"67-70"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/bc/ejr-10-2-67.PMC10544436.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9837440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When the Mimic Coexists with the Mimicked.","authors":"Ufuk İlgen,&nbsp;Zeliha Ademoğlu,&nbsp;Kübra Erol Kalkan,&nbsp;Tülin Deniz Yalta,&nbsp;Hakan Emmungil","doi":"10.5152/eurjrheum.2023.21212","DOIUrl":"10.5152/eurjrheum.2023.21212","url":null,"abstract":"A 77-year-old male presented with blurred vision in the left eye for the last few weeks. Optic disc on the left was pale and edematous on eye examination. The best uncorrected visual acuity in the right and left eyes was 6/9 and 6/21, respectively. He was reported to have bitemporal headaches as well. Both superficial temporal arteries were hard and nodular with no tenderness on palpation. Erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) were 80 mm/h and 45 mg/L, respectively. Complete blood count and serum biochemistry were normal. Although the walls of the superficial temporal arteries were thickened and segmentally stenotic on color Doppler ultrasonography, no characteristic halo sign could be detected. Intravenous pulse methylprednisolone 1 g/day for 3 days followed by 48 mg/day p.o. was initiated after temporal artery biopsy. Visual acuity in the left eye increased gradually to 6/15 and 6/12 at the end of the first and second weeks of corticosteroid therapy, respectively. Erythrocyte sedimentation rate and CRP returned to their normal values as well.","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"86-87"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/f1/ejr-10-2-86.PMC10544443.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9837078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse Idiopathic Skeletal Hyperostosis in a Young Male.","authors":"Ashish Sharma,&nbsp;Ashok Kumar,&nbsp;Anunay Agarwal","doi":"10.5152/eurjrheum.2023.22072","DOIUrl":"10.5152/eurjrheum.2023.22072","url":null,"abstract":"","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"84-85"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/6b/ejr-10-2-84.PMC10544329.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10214605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Triggering Receptor Expressed on Myeloid Cells-Like Transcript-1 Antibodies in Systemic Lupus Erythematosus.","authors":"Luis M Vilá, Mariely Nieves-Plaza, Xariana Vales Torres, Benjamín Nieves, A Valance Washington","doi":"10.5152/eurjrheum.2023.22051","DOIUrl":"10.5152/eurjrheum.2023.22051","url":null,"abstract":"","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"88-89"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/5e/ejr-10-2-88.PMC10544204.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9825200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review of Non-surgical Therapies for Osteoarthritis of the Hand: An Update.","authors":"Haonan Mi, Christopher Oh, Tanveer Towheed","doi":"10.5152/eurjrheum.2023.21197","DOIUrl":"10.5152/eurjrheum.2023.21197","url":null,"abstract":"<p><p>Hand osteoarthritis is a common disease with significant morbidity. This review aimed to update our earlier systematic reviews which included all published randomized controlled trials evaluating pharmacological and non-pharmacological therapies in patients with hand osteoarthritis. A total of 133 randomized controlled trials evaluating pharmacological and nonpharmacological therapies in hand osteoarthritis were reviewed. Overall, the methodological quality of randomized controlled trials has improved since the last update. Almost all new studies described their methods for randomization, blinding, and allocation concealment. However, studies continued to underreport features specific to hand osteoarthritis, such as pattern of joint involvement and number of affected joints. Standardized outcome assessments for pain and function were commonly presented, but measures of other hand osteoarthritis specific outcomes, such as health-related quality of life and patient global assessments, continued to be underreported. Future trials should consistently report on hand osteo arthritis specific features and outcome assessments in order to make clinically relevant conclusions about the efficacy of the diverse treatment options available.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11184966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10658914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}